To ascertain any therapeutic opportunities for the improved management of drug-resistant breast cancer, we looked at the approach of using combinations of anti-endocrine agents with a variety of tyrosine kinase inhibitors (TKIs) directed against HER1 and HER2. This evidence concerns the gene ERBB2 and breast carcinoma.